News for Eli Lilly and Company (LLY.DE)

SAN FRANCISCO and SUZHOU, China, June 13, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations. Details are listed below：

Market Analysis by covering: Nasdaq 100, S&P 500, Dow Jones Industrial Average, Microsoft Corporation. Read 's Market Analysis on Investing.com

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that Denice M. Torres has been elected to the company's Boa

“Buy low, sell high” is a common investing mantra. It’s easy to understand, but often hard to execute because emotion gets in the way. When great stocks are sale, things are often bleak.

Market Analysis by covering: Nasdaq 100, S&P 500, Eli Lilly and Company, SPDR® S&P 500® ETF Trust. Read 's Market Analysis on Investing.com

SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination of sintilimab and fruquintinib for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (TKI) has been accepted for review by the China National Medical Products Administration (NMPA).

**media[646188]**

HGS names new Global CEO, Eli Lilly partners with Apollo Group, NLC India forms JV, ICAI probes IndusInd Bank.

PR NewswireINDIANAPOLIS, May 29, 2025 INDIANAPOLIS, May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies o

Eli Lilly (LLY) to present data from multiple studies at ADA's 85th Scientific Sessions, June 20-23, 2025. Key presentations include Phase 3 trial resul

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks...

Purdue’s Mung Chiang outlines a bold vision to transform university research funding through deeper industry, philanthropic, and public-private partnerships.

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Eli Lilly and Company LLY. “I just think this is a decent level to start a position i...

**media[637529]**

Eli Lilly and Company (NYSE:LLY) recently announced that Australia's Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing.

PR NewswireINDIANAPOLIS, May 22, 2025 INDIANAPOLIS, May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies o

PR NewswireINDIANAPOLIS, May 21, 2025 The authorization in Australia is for adult patients who are Apolipoprotein E-ε4 heterozygotes or non-carriers INDIA

Lilly's Kisunla (donanemab) gains 13th global approval in Australia for Alzheimer's treatment. Clinical trials indicate up to 35% slower

**media[632444]**